338 related articles for article (PubMed ID: 19409543)
1. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.
Partridge AH; Ruddy KJ; Gelber S; Schapira L; Abusief M; Meyer M; Ginsburg E
Fertil Steril; 2010 Jul; 94(2):638-44. PubMed ID: 19409543
[TBL] [Abstract][Full Text] [Related]
2. Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients.
Elgindy EA; El-Haieg DO; El-Sebaey A
Fertil Steril; 2008 Jun; 89(6):1670-6. PubMed ID: 17658520
[TBL] [Abstract][Full Text] [Related]
3. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
[TBL] [Abstract][Full Text] [Related]
4. Antimüllerian hormone as a measure of reproductive function in female childhood cancer survivors.
Lunsford AJ; Whelan K; McCormick K; McLaren JF
Fertil Steril; 2014 Jan; 101(1):227-31. PubMed ID: 24083876
[TBL] [Abstract][Full Text] [Related]
5. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
[TBL] [Abstract][Full Text] [Related]
6. Ovarian reserve after treatment with alkylating agents during childhood.
Thomas-Teinturier C; Allodji RS; Svetlova E; Frey MA; Oberlin O; Millischer AE; Epelboin S; Decanter C; Pacquement H; Tabone MD; Sudour-Bonnange H; Baruchel A; Lahlou N; De Vathaire F
Hum Reprod; 2015 Jun; 30(6):1437-46. PubMed ID: 25801499
[TBL] [Abstract][Full Text] [Related]
7. Measuring ovarian function in young cancer survivors.
Su HI
Minerva Endocrinol; 2010 Dec; 35(4):259-70. PubMed ID: 21178920
[TBL] [Abstract][Full Text] [Related]
8. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers.
Reh A; Oktem O; Oktay K
Fertil Steril; 2008 Nov; 90(5):1635-9. PubMed ID: 18166178
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of anti-Müllerian hormone as a test for the prediction of ovarian reserve.
Kwee J; Schats R; McDonnell J; Themmen A; de Jong F; Lambalk C
Fertil Steril; 2008 Sep; 90(3):737-43. PubMed ID: 17923131
[TBL] [Abstract][Full Text] [Related]
10. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
[TBL] [Abstract][Full Text] [Related]
11. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology?
Muttukrishna S; McGarrigle H; Wakim R; Khadum I; Ranieri DM; Serhal P
BJOG; 2005 Oct; 112(10):1384-90. PubMed ID: 16167941
[TBL] [Abstract][Full Text] [Related]
12. Impact of tamoxifen therapy on fertility in breast cancer survivors.
Shandley LM; Spencer JB; Fothergill A; Mertens AC; Manatunga A; Paplomata E; Howards PP
Fertil Steril; 2017 Jan; 107(1):243-252.e5. PubMed ID: 27887709
[TBL] [Abstract][Full Text] [Related]
13. Statistically significant changes of antimüllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women.
Wunder DM; Bersinger NA; Yared M; Kretschmer R; Birkhäuser MH
Fertil Steril; 2008 Apr; 89(4):927-33. PubMed ID: 17603052
[TBL] [Abstract][Full Text] [Related]
14. Dehydroepiandrosterone supplementation improves predictive markers for diminished ovarian reserve: serum AMH, inhibin B and antral follicle count.
Yilmaz N; Uygur D; Inal H; Gorkem U; Cicek N; Mollamahmutoglu L
Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(2):257-60. PubMed ID: 23664458
[TBL] [Abstract][Full Text] [Related]
15. Heterozygosity for the classical galactosemia mutation does not affect ovarian reserve and menopausal age.
Knauff EA; Richardus R; Eijkemans MJ; Broekmans FJ; de Jong FJ; Fauser BC; Bosch AM
Reprod Sci; 2007 Dec; 14(8):780-5. PubMed ID: 18089596
[TBL] [Abstract][Full Text] [Related]
16. Impact of cancer therapies on ovarian reserve.
Gracia CR; Sammel MD; Freeman E; Prewitt M; Carlson C; Ray A; Vance A; Ginsberg JP
Fertil Steril; 2012 Jan; 97(1):134-40.e1. PubMed ID: 22137491
[TBL] [Abstract][Full Text] [Related]
17. Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection.
Wunder DM; Guibourdenche J; Birkhäuser MH; Bersinger NA
Fertil Steril; 2008 Dec; 90(6):2203-10. PubMed ID: 18291376
[TBL] [Abstract][Full Text] [Related]
18. Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors.
McCune JS; Games DM; Espirito JL
J Oncol Pharm Pract; 2005 Jun; 11(2):37-43. PubMed ID: 16460603
[TBL] [Abstract][Full Text] [Related]
19. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
[TBL] [Abstract][Full Text] [Related]
20. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
